Recursion Pharmaceuticals, Inc.
NASDAQ:RXRXBiotechnology
+$0.04 today
- Market cap
- $1.76B
- Beta
- 1.00
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$1.06
Volume 41.13M
Average 15.60M
RXRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Recursion Pharmaceuticals, Inc.NASDAQ: RXRX
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income declines year over year
Q2 FY2026 net income of $131.01M (cash outflow) fell 23.8% year over year, behind the -20.1% change in trailing-twelve-month net income. Sequentially, it rose 11.5% from the prior quarter. Over 3 fiscal years it compounded at +39.1% a year.
Context
- Net income amounted to 863.4% of revenue in FY2025, up 75.3 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$398.74M (-38.2%) for the fiscal year ending Dec 2026, a slowdown from the +39.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$131.01M+11.5% QoQ
- Last fiscal yearDec 2025
- -$644.76M+39.1% YoY
- LTMJun 2026
- -$518.88M-20.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -23.8% | -26.7% | -2.9 pp |
| 1 year | +39.1% | -38.2% | -77.2 pp |
| 3-year CAGR | +39.1% | -19.1% | -58.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (644.76M) USD
- Year-over-year change
- -39.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (644.76M) | -39.1% |
| FY2024 | 2024-12-31 | (463.66M) | -41.3% |
| FY2023 | 2023-12-31 | (328.07M) | -37.0% |
| FY2022 | 2022-12-31 | (239.48M) | -28.4% |
| FY2021 | 2021-12-31 | (186.48M) | — |
Net Income vs competitors
How RXRX compares with its peers on the latest reported figures
- RXRX's LTM Jun 2026 net income of $518.88M is the largest of the 4 companies compared; the peer median is $286.04M.
- Its year-over-year change of -20.1% is the 3rd highest of 4, against a peer median of -8.2%.
- Net income amounts to 945.9% of revenue for RXRX, versus a peer median of 2763.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $518.88M | -20.1% | +39.1% | 945.9% | |
| LTM Jun 2026 | $511.45M | +6.8% | +16.3% | 14191.2% | |
| LTM Jun 2026 | $286.04M | -8.2% | -1.6% | 2763.6% | |
| LTM Mar 2026 | $122.54M | -335.9% | +4.5% | 612.7% | |
| Peer median (excluding RXRX) | $286.04M | -8.2% | +4.5% | 2763.6% | |
Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (186.48M) | (239.48M) | (328.07M) | (463.66M) | (644.76M) |
| Depreciation & Amortization | 8.41M | 11.76M | 24.4M | 36.49M | 83.7M |
| Deferred Income Tax | 827K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.84M | 27.91M | 53.5M | 81.69M | 111.22M |
| Change in Working Capital | (306K) | 104.92M | (44.26M) | (38M) | 13.69M |
| Accounts Receivables | 114K | (2K) | (7.76M) | (6.07M) | 32.94M |
| Inventory | 7.84M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.75M | 1.77M | (987K) | 6.44M | (2.62M) |
| Other Working Capital | (10M) | 103.16M | (35.51M) | (38.37M) | (16.64M) |
| Other Non-Cash Items | 4.1M | 11.37M | 6.64M | 24.31M | 64.34M |
| Operating Cash Flow | (158.61M) | (83.52M) | (287.78M) | (359.17M) | (371.81M) |
| Capital Expenditures | (39.8M) | (37.36M) | (11.96M) | (13.7M) | (6.47M) |
| Acquisitions (Net) | 231.95M | 0 | 1.84M | 277.1M | 0 |
| Purchases of Investments | (301.14M) | 0 | 0 | 0 | (3.81M) |
| Sales of Investments | 69.19M | 230.61M | 480K | 0 | 0 |
| Other Investing Activities | (231.95M) | (300K) | (597K) | (3.35M) | (6.6M) |
| Investing Cash Flow | (271.74M) | 193.25M | (10.23M) | 260.06M | (16.87M) |
| Debt Repayment | (12.8M) | (90K) | (766K) | (4.44M) | (8.43M) |
| Common Stock Issued | 462.9M | 143.71M | 128.09M | 300.42M | 532.96M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.44M | 10.72M | 12.81M | 8.14M | (3M) |
| Financing Cash Flow | 458.54M | 154.35M | 140.13M | 304.12M | 521.53M |
| Effect of Forex Changes | 0 | (307K) | 188K | (3.41M) | 18.04M |
| Net Change in Cash | 28.18M | 263.76M | (157.69M) | 201.6M | 150.9M |
| Free Cash Flow | (198.41M) | (120.88M) | (300.33M) | (372.87M) | (378.28M) |
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
Intrinsic Alpha fair value
Locked
Current Price
$2.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.